Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9 (1), 48-60

The Effects of Ketamine on Suicidality Across Various Formulations and Study Settings

The Effects of Ketamine on Suicidality Across Various Formulations and Study Settings

David Dadiomov et al. Ment Health Clin.


Introduction: Suicidality and self-injurious behavior afflict patients with a wide variety of psychiatric illnesses. Currently, there are few pharmacologic treatments for suicidality and self-injurious behavior and none that treat these conditions emergently. Recently, ketamine has demonstrated efficacy in treating both depression and acute suicidal ideation. An increasing usage of ketamine, of a variety of formulations, has been studied for these indications. This article reviews the evidence for use of ketamine in self-injurious behavior and suicidality.

Methods: A review of the MEDLINE database for articles relating to ketamine, self-injurious behavior, suicidality, and self-harm was conducted. Additional articles were assessed via cross-reference.

Results: A total of 24 articles that included clinical trials, meta-analyses, case series, and case reports were analyzed. The majority of studies of ketamine for suicidal ideation include the intravenous route using a dose of 0.5 mg/kg over 40 minutes. These studies suggest that intravenous ketamine may be effective at reducing suicidal ideation acutely. Data on use of ketamine in the intramuscular, intranasal, and oral forms are limited and of poorer quality. Studies on these formulations contain greater variability of positive and negative results of ketamine for reducing suicidality and self-injurious behavior. The durability of the antisuicidal effects across all formulations is limited.

Discussion: Ketamine may be an effective option for the treatment of suicidal ideation in patients across inpatient, outpatient, or emergent settings. At this time, more research is needed on the efficacy of ketamine across all formulations being used in clinical practice.

Keywords: ketamine; self-harm; self-injurious behavior; suicidal.

Conflict of interest statement

Disclosures: No disclosures or conflicts of interest for D.D. At the time of writing, D.D. was a PGY2 Psychiatric Pharmacy Resident at University of California San Diego Health in San Diego, CA. K.L. is a consultant for Shire, Takeda Pharmaceuticals, and Otsuka Pharmaceuticals.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles


    1. Cipriano A, Cella S, Cotrufo P. Nonsuicidal self-injury: a systematic review. Front Psychol. 2017;8:1946. doi: 10.3389/fpsyg.2017.01946. 29167651 DOI: 10.3389/fpsyg.2017.01946 PubMed PMID: PubMed PMID: 29167651. - DOI - PMC - PubMed
    1. World Health Organization [Internet] Preventing suicide: a global imperative. 2018 [cited. Jun 11]. Available from:
    1. Olfson M, Wall M, Wang S, Crystal S, Gerhard T, Blanco C. Suicide following deliberate self-harm. Am J Psychiatry. 2017;174(8):765–74. doi: 10.1176/appi.ajp.2017.16111288. 28320225 DOI: 10.1176/appi.ajp.2017.16111288 PubMed PMID: PubMed PMID: 28320225. - DOI - PubMed
    1. de Cates AN, Broome MR. Can we use neurocognition to predict repetition of self-harm, and why might this be clinically useful? A perspective. Front Psychiatry. 2016;7:7. doi: 10.3389/fpsyt.2016.00007. 26858659 DOI: 10.3389/fpsyt.2016.00007 PubMed PMID: PubMed PMID: 26858659. - DOI - PMC - PubMed
    1. Kinchin I, Doran CM, Hall WD, Meurk C. Understanding the true economic impact of self-harming behaviour. Lancet Psychiatry. 2017;4(12):900–1. doi: 10.1016/S2215-0366(17)30411-X. 29179929 DOI: 10.1016/S2215-0366(17)30411-X PubMed PMID: PubMed PMID: 29179929. - DOI - PubMed

LinkOut - more resources